252 related articles for article (PubMed ID: 34789538)
1. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.
Malani D; Kumar A; Brück O; Kontro M; Yadav B; Hellesøy M; Kuusanmäki H; Dufva O; Kankainen M; Eldfors S; Potdar S; Saarela J; Turunen L; Parsons A; Västrik I; Kivinen K; Saarela J; Räty R; Lehto M; Wolf M; Gjertsen BT; Mustjoki S; Aittokallio T; Wennerberg K; Heckman CA; Kallioniemi O; Porkka K
Cancer Discov; 2022 Feb; 12(2):388-401. PubMed ID: 34789538
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine.
Wang H; Chan KYY; Cheng CK; Ng MHL; Lee PY; Cheng FWT; Lam GKS; Chow TW; Ha SY; Chiang AKS; Leung WH; Leung AYH; Wang CC; Zhang T; Zhang XB; So CC; Yuen YP; Sun Q; Zhang C; Xu Y; Cheung JTK; Ng WH; Tang PM; Kang W; To KF; Lee WYW; Wong RSM; Poon ENY; Zhao Q; Huang J; Chen C; Yuen PMP; Li CK; Leung AWK; Leung KT
Blood Cancer Discov; 2022 Nov; 3(6):516-535. PubMed ID: 35960210
[TBL] [Abstract][Full Text] [Related]
3. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
4. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
5. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.
Swords RT; Azzam D; Al-Ali H; Lohse I; Volmar CH; Watts JM; Perez A; Rodriguez A; Vargas F; Elias R; Vega F; Zelent A; Brothers SP; Abbasi T; Trent J; Rangwala S; Deutsch Y; Conneally E; Drusbosky L; Cogle CR; Wahlestedt C
Leuk Res; 2018 Jan; 64():34-41. PubMed ID: 29175379
[TBL] [Abstract][Full Text] [Related]
6. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
Derman BA; Larson RA
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101102. PubMed ID: 31779969
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).
Schnetzke U; Fix P; Spies-Weisshart B; Schrenk K; Glaser A; Fricke HJ; La Rosée P; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1391-7. PubMed ID: 24728467
[TBL] [Abstract][Full Text] [Related]
8. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
10. The road to precision oncology.
Biankin AV
Nat Genet; 2017 Feb; 49(3):320-321. PubMed ID: 28232728
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
12. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers.
Acanda De La Rocha AM; Berlow NE; Fader M; Coats ER; Saghira C; Espinal PS; Galano J; Khatib Z; Abdella H; Maher OM; Vorontsova Y; Andrade-Feraud CM; Daccache A; Jacome A; Reis V; Holcomb B; Ghurani Y; Rimblas L; Guilarte TR; Hu N; Salyakina D; Azzam DJ
Nat Med; 2024 Apr; 30(4):990-1000. PubMed ID: 38605166
[TBL] [Abstract][Full Text] [Related]
14. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
[TBL] [Abstract][Full Text] [Related]
15. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
16. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
Ye P; Pei R; Jin J; Sun J; Li K; Cao J; Zhou D; Lu Y
Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
[TBL] [Abstract][Full Text] [Related]
17. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
Miyamoto K; Minami Y
Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Burd A; Levine RL; Ruppert AS; Mims AS; Borate U; Stein EM; Patel P; Baer MR; Stock W; Deininger M; Blum W; Schiller G; Olin R; Litzow M; Foran J; Lin TL; Ball B; Boyiadzis M; Traer E; Odenike O; Arellano M; Walker A; Duong VH; Kovacsovics T; Collins R; Shoben AB; Heerema NA; Foster MC; Vergilio JA; Brennan T; Vietz C; Severson E; Miller M; Rosenberg L; Marcus S; Yocum A; Chen T; Stefanos M; Druker B; Byrd JC
Nat Med; 2020 Dec; 26(12):1852-1858. PubMed ID: 33106665
[TBL] [Abstract][Full Text] [Related]
19. Precision medicine for acute myeloid leukemia.
Lai C; Karp JE; Hourigan CS
Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
